# Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

> **NCT00971932** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 33 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Cisplatin/Carboplatin
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT00971932
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-03
- **Final completion:** —
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00971932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00971932, "Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00971932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*